AlphaMark Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

AlphaMark Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-750	Closed	-$12K	–	809
2024 Q2	$12K	Hold	750	–	–	﹤0.01%	510
2024 Q1	$11K	Hold	750	–	–	﹤0.01%	524
2023 Q4	$8K	Hold	750	–	–	﹤0.01%	555
2023 Q3	$8K	Hold	750	–	–	﹤0.01%	544
2023 Q2	$6K	Hold	750	–	–	﹤0.01%	475
2023 Q1	$7K	Hold	750	–	–	﹤0.01%	466
2022 Q4	$7K	Hold	750	–	–	﹤0.01%	430
2022 Q3	$6K	Hold	750	–	–	﹤0.01%	484
2022 Q2	$6K	Hold	750	–	–	﹤0.01%	454
2022 Q1	$7K	Hold	750	–	–	﹤0.01%	442
2021 Q4	$6K	Buy	+750	New	+$6.77K	﹤0.01%	441
2019 Q1	–	Sell	-1,575	Closed	-$24K	–	516
2018 Q4	$24K	Buy	+1,575	New	+$32.3K	0.01%	236

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

AlphaMark Advisors's TEVA Position: Q3 2024 in Review

AlphaMark Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 750 shares — an estimated $12K sold.

AlphaMark Advisors first reported a position in TEVA in Q4 2018 and held it in 12 quarters. The position peaked at $24K in Q4 2018. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

AlphaMark Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
AlphaMark Advisors sold 750 Teva Pharmaceuticals shares in Q3 2024, an estimated $12K.
AlphaMark Advisors first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 12 quarters.
AlphaMark Advisors's Teva Pharmaceuticals position peaked at $24K in Q4 2018.
543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on AlphaMark Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.